Aurobindo's Acrotech unit launches dermatology drug in US market

Aurobindo Pharmaceuticals' Acrotech division has marked its entry into the US dermatology market with the introduction of Adquey, expanding the Indian pharmaceutical company's footprint in a key therapeutic segment. The launch represents a strategic move to capture opportunities in the specialized dermatology space in the world's largest pharmaceutical market.

To support the commercial rollout and drive growth in dermatology, Acrotech has established a dedicated business unit focused specifically on this therapeutic area. The move reflects the company's commitment to building sustained presence and capabilities in the dermatology segment, which has shown consistent demand and growth potential in the US healthcare market.

The initiative aligns with Aurobindo's broader strategy to expand its specialty pharmaceutical offerings and diversify its product portfolio across therapeutic segments. By creating a focused business structure, the company aims to leverage specialized expertise and resources to effectively penetrate and compete in the US dermatology market, where branded and specialty formulations command significant value.

Acrotech's entry into US dermatology adds to Aurobindo's existing operations in North America, where the company has established itself as a significant player in generic pharmaceuticals. The dermatology segment entry signals the company's intent to move beyond generic formulations and build a stronger presence in specialty and branded pharmaceutical categories.